Intuitive Surgical Stock Surges After FDA Clearance for Next-Gen Robotic Surgery
Intuitive Surgical (ISRG) Soars After FDA Clearance for da Vinci 5 Robotic Surgery System
In a groundbreaking development, Intuitive Surgical’s stock saw a significant increase of over 3% in after-hours trading on Thursday following the news of FDA clearance for its latest robotic surgery system, da Vinci 5. The company’s CEO, Gary Guthart, expressed his excitement about the new system, highlighting the significant improvements it will bring to the field of surgery.
Guthart stated that the da Vinci 5 will not only enhance patient outcomes but also improve the overall experience for both patients and care teams. Additionally, he emphasized that the new system will lead to lower overall costs of care, making it a game-changer in the industry.
The da Vinci 5 is a step up from the company’s previous system, da Vinci Xi, featuring advancements in accuracy, precision, and technology. With its next-generation three-dimensional display, improved image processing, force-sensing technology, and enhanced throughput, the system boasts an impressive 10,000 times the computing power of its predecessor.
Intuitive Surgical plans to first launch the da Vinci 5 for a select group of U.S. surgeons who collaborated during its development, followed by a broader rollout. The company’s stock has continued to perform well, remaining above key moving averages since November, according to MarketSurge.com.
In other news within the medical industry, Dexcom and Exact Sciences are making waves in the diabetes market, while Cathie Wood’s Exact Sciences and Guardant Health are also making headlines. Investors looking for growth opportunities can stay updated on the best growth stocks to buy and watch through IBD’s Investing Strategies show and receive timely buy and sell alerts with IBD Leaderboard.
For more updates on Intuitive Surgical and other top healthcare companies, follow Allison Gatlin on X (previously known as Twitter) at @IBD_AGatlin.
